DOTA Zoledronate

• Description :

  DOTA Zoledronate is a next-generation agent for bone targeted radionuclide therapy for diagnosing bone metastases[1].

• UNSPSC :

  12352005

• Target :

  Radionuclide-Drug Conjugates (RDCs)

• Type :

  Reference compound

• Related Pathways :

  Antibody-drug Conjugate/ADC Related

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/dota-zoledronate.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(CN1CCN(CCN(CCN(CC1)CC(O)=O)CC(NCCC2=CN(CC(P(O)(O)=O)(O)P(O)(O)=O)C=N2)=O)CC(O)=O)O

• Molecular Formula :

  C23H41N7O14P2

• Molecular Weight :

  701.56

• References & Citations :

  [1]The ITM Group Announces In-Licensing of DOTA-Zoledronate Theranostic Agent.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1908409-18-6]